| Note |
The first antidepressant of the RIMA class is here. Reversible Inhibitor of Monoamine-oxidase A. Out of the darkness and into the light. A new approach to major depression. Experience around the world…Since 1989, physicians in 50 countries have proven the value of the first RIMA antidepressant in over 37 million patient days. Efficacy equal to tricyclics. Results of a large multi-centre Canadian trial have shown Manerix to be equally effective as amitriptyline, but far better tolerated. A tolerability profile similar to placebo. The product monograph confirms it: you and your patients can expect a low incidence of anticholinergic and cardiovascular side effects, virtually no change in weight, and a low potential for sedation, agitation, nausea, sexual dysfunction and other side effects commonly associated with antidepressant therapies. Manerix is relatively safe. Manerix offers a better margin of safety in overdose than tricyclic antidepressants. What's more, there is a low risk of interaction with commonly prescribe drugs and alcohol. Consider Manerix as first line therapy. With Manerix, you can initiate treatment using a therapeutic dose. In addition, Manerix has a convenient washout period of just 2 days. |
